Thirty-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement

A new focus on mitral and tricuspid valve disease - EuroPCR 2022Подробнее

Thirty-day outcomes of a new self-expanding transcatheter heart valve - EuroPCR 2017Подробнее

HIGHLIFE Trans-Septal Mitral Valve Replacement (TSMVR) - clinical study update - EuroPCR 2021Подробнее

Intrepid early experience - PCR London Valves 2021Подробнее

Heart Minute | TAVR Outcomes in Patients With MRПодробнее

Dr Peter Hansen: Transcatheter Mitral Valve TherapiesПодробнее

Transfemoral Transeptal Mitral valve replacement (VIV) using MyVal 27.5 mmПодробнее

Transcatheter mitral valve replacement: patient selection and hemodynamic stabilityПодробнее

Transseptal transcatheter mitral valve replacement in severe mitral annular calcificationПодробнее

Catheter Based Mitral Valve Replacement – Where Do We Stand In 2022Подробнее

How can we improve outcomes for our patients with Mitral Regurgitation? - less is more - WebinarПодробнее

Mitral and tricuspid transcatheter valves therapies: time to innovate!Подробнее

The Interaction of FEV1 and NT-Pro-BNP with Outcomes after Transcatheter Aortic Valve ReplacementПодробнее

Transcatheter mitral valve replacement and repair: why do we need both - EuroPCR 2021Подробнее

Transcatheter MVR for MAC - Mayra Guerrero, MDПодробнее

Mitral Valve-In-Valve Procedure with Transcatheter DeviceПодробнее

HFSA 24: EXPANDed: Atrial Secondary MR Outcomes Following TEERПодробнее

Will This Heart Valve Replacement Last a Lifetime?Подробнее

Transcatheter Mitral Valve-in-Valve Procedure After Bioprosthetic Valve FailureПодробнее